Marker expression | Patients, n (%) | Median survival (months) | 5-Year survival (%) | P | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | A | M | W | A | M | W | A | M | W | A | M | W |
p-Akt Thr 308 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 131(53) | 59 (55) | 72 (52) | 91 | NR | 80 | 55 | 56 | 54 | 0.002 | 0.009 | 0.064 |
High | 113 (45) | 48 (44) | 65 (47) | 29 | 26 | 31 | 35 | 33 | 36 | Â | Â | Â |
Missing | 5 (2) | 3 (1) | 2 (1) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
p-Akt Ser 473 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 70 (28) | 35 (32) | 35 (25) | 62 | 41 | 127 | 51 | 45 | 57 | 0.074 | 0.868 | 0.023 |
High | 174 (70) | 74 (67) | 100 (72) | 31 | 41 | 29 | 43 | 46 | 40 | Â | Â | Â |
Missing | 5 (2) | 1 (1) | 4 (3) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Akt2 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 82 (33) | 41 (37) | 41 (39) | 123 | NR | 80 | 58 | 56 | 59 | 0.008 | 0.062 | 0.064 |
High | 163 (65) | 68 (62) | 95 (68) | 31 | 31 | 31 | 41 | 42 | 40 | Â | Â | Â |
Missing | 4 (2) | 1 (1) | 3 (3) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Akt3 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 177 (71) | 81 (74) | 96 (69) | 62 | 63 | 57 | 51 | 51 | 50 | 0.067 | 0.207 | 0.197 |
High | 60 (24) | 22 (20) | 38 (27) | 31 | 27 | 38 | 35 | 33 | 36 | Â | Â | Â |
Missing | 12 (5) | 7 (6) | 5 (4) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
PI3K | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Negative | 104 (42) | 44 (40) | 60 (43) | NR | NR | 127 | 60 | 57 | 63 | <0.001 | 0.078 | <0.001 |
Positive | 136 (56) | 61 (55) | 75 (54) | 29 | 37 | 23 | 37 | 41 | 33 | Â | Â | Â |
Missing | 9 (4) | 5 (5) | 4 (3) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
PTEN | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Negative | 88 (35) | 37 (34) | 51 (37) | 80 | NR | 80 | 51 | 51 | 51 | 0.259 | 0.658 | 0.198 |
Positive | 148 (59) | 67 (61) | 81 (58) | 41 | 41 | 38 | 46 | 48 | 44 | Â | Â | Â |
Missing | 13 (6) | 5 (5) | 7 (5) | Â | Â | Â | Â | Â | Â | Â | Â | Â |